At the 2026 JPMorgan Healthcare Conference, Dan Skovronsky, Eli Lilly’s chief scientific officer, outlined a strategic shift from one-size-fits-all obesity injections to a diversified portfolio including oral GLP-1 options and combination regimens. Lilly plans to launch its first oral obesity pill later this year, following December data showing patients maintained over 80% of initial weight loss after switching from weekly injections. The company is also advancing retatrutide, its triple-hormone injectable, with Phase 3 results next quarter expected to build on the 28% mean weight loss achieved at week 68 in late-stage trials.

Lilly and Novo Nordisk together serve approximately 15 million patients with obesity on GLP-1 therapies. Lilly has cut cash prices on its weekly injections by up to 30% over the past year and struck a landmark agreement with the administration in November to secure Medicare coverage for obesity drugs, a first for the sector. These measures aim to unlock treatment for the remaining 95 million Americans classified as obese or overweight, supporting analyst forecasts of a nearly $100 billion annual market by 2030.

In January, Lilly secured FDA Breakthrough Therapy designation for its sofetabart mipitecan candidate in platinum-resistant ovarian cancer, expanding its oncology pipeline beyond metabolic disorders. The company will report fourth-quarter 2025 financial results on February 4, 2026, hosting a live investor webcast at 10 a.m. Eastern. Management guidance indicates continued double-digit revenue growth driven by weight-loss portfolio expansion and late-stage readouts across four pivotal trials this year.